60% Complete Response Rate after JELMYTO Induction 25% of Patients Received a Ureteral Stent “The retrograde instillation of JELMYTO for the clinical management of low-grade upper tract urothelial ...
Retrograde study showed a mitral-valve gradient of 25 mm. of mercury, a calculated forward-valve area of 0.3 square centimeter and an elevated pulmonary arteriolar resistance. An angiocardiogram (Fig.
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results